Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 S-Trimer
- Development stage
- Preclinical
- Lead developer
- Wuhan Binhui Biopharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SARS-CoV-2 S-Trimer is a recombinant protein vaccine developed by Binhui Biopharmaceutical Co., Ltd. It is designed as a booster shot for individuals who have previously received two doses of an inactivated SARS-CoV-2 vaccine. The vaccine aims to enhance neutralizing antibody levels and provide protection against emerging SARS-CoV-2 variants by targeting the S-Trimer protein of the virus.
- Other names
- recombinant SARS-CoV-2 S-Trimer vaccine
02
Targets
γδ TCR (T-cell receptor)ACE2 (Angiotensin-converting enzyme 2)BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on SARS-CoV-2 S-Trimer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 S-Trimer.